2023 World Conference on Lung Cancer (Posters)-P2.12. Beware: Tyrosine Kinase Inhibitors for Lung Cancers that Inhibit MATE-1 can Lead to "False” Decreases in Renal Function

P2.12. Beware: Tyrosine Kinase Inhibitors for Lung Cancers that Inhibit MATE-1 can Lead to "False” Decreases in Renal Function - PDF(Abstract)

Back to course

Pdf Summary

A group of researchers conducted a study to determine the potential impact of tyrosine kinase inhibitors (TKIs) on kidney function in lung cancer patients. TKIs are often used to treat certain types of lung cancer, but they can also inhibit a protein called MATE-1, which can lead to an increase in serum creatinine levels, indicating reduced kidney function. The researchers reviewed data from 776 lung cancer patients who were treated with various TKIs and found that 11% of them experienced acute kidney injury (AKI). However, when they recalculated the glomerular filtration rate (GFR) using a different marker of kidney function called cystatin C, they found that the estimated GFR improved in almost all cases. This suggests that the increase in serum creatinine levels may not be indicative of true kidney damage and may instead be a result of MATE-1 inhibition by the TKIs. Therefore, the researchers recommend that in cases where AKI occurs in patients receiving MATE-1 inhibitors, the GFR should be recalculated using cystatin C before considering alternative causes or adjusting the TKI treatment. This research highlights the importance of considering the potential impact of TKIs on kidney function and the need for more accurate markers of kidney function in cancer patients receiving these medications.

Asset Subtitle

Monica Chen

Meta Tag

Speaker Monica Chen

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

tyrosine kinase inhibitors

kidney function

lung cancer patients

MATE-1 inhibition

serum creatinine levels

acute kidney injury

glomerular filtration rate

cystatin C

alternative causes

TKI treatment